What is SEPN's current stock price?

SEPN (Septerna, Inc.) is currently trading at $28.36 with a market cap of $1.28B.

What sector is Septerna, Inc. in?

Septerna, Inc. (SEPN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SEPN a good stock to buy?

Analysts have a Buy consensus on SEPN with a price target of $41.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SEPN Septerna, Inc.

Healthcare

$28.36+1.58%ClosedMarket Cap: $1.28B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.35

P/S

17.69

EV/EBITDA

-18.48

DCF Value

$-22.11

FCF Yield

8.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.4%

Operating Margin

-77.1%

Net Margin

-49.9%

ROE

-9.4%

ROA

-6.3%

ROIC

-11.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$26.5M	$-8.6M	$—
Q4 null	$24.1M	$-10.7M	$—
FY null	$46.0M	$-48.9M	$—
Q3 null	$21.5M	$8.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$41.75

Target (Median)

$36.50

Target Range

$34.00 - $60.00

1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-13

JP MorganOverweight

2026-03-24

Truist SecuritiesBuy

2026-03-11

Wells FargoOverweight

2026-03-03

HC Wainwright & Co.Buy

2026-03-02

Trading Activity

Insider Trades

View All

Bhatt Elizabethofficer: President and COO

SellFri Apr 17

Bhatt Elizabethofficer: President and COO

SellFri Apr 17

Bhatt Elizabethofficer: President and COO

SellFri Apr 17

Bhatt Elizabethofficer: President and COO

SellFri Apr 17

Shaikhly Samiraofficer: Chief People Officer

SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.20

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Peers